We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 07, 2021

Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer in Premenopausal Women

Breast Cancer Research


Additional Info

Breast Cancer Research
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Breast Cancer Res 2021 Aug 23;23(1)87, P Neven, HS Rugo, SM Tolaney, H Iwata, M Toi, MP Goetz, PA Kaufman, Y Lu, N Haddad, KC Hurt, GW Sledge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading